AzTrials
AzTrials

Colorectal Cancer Postoperative ComplicationsKIA-KorektNCT07537491

KIA-Korekt: Staged Unimodal-to-Multimodal AI Evaluation for Perioperative Risk Prediction in Colorectal Cancer

An observational study of Colorectal Cancer Postoperative Complications, run by Rene Mantke at 1 site in Germany.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Perioperative complications following surgery for colorectal cancer (CRC) represent a major cause of postoperative morbidity and mortality. Existing risk stratification tools lack the precision to capture the complex biological and morphological factors that determine individual patient vulnerability. Read more about this study

Who is it for?
Ages 18 years and older
How many people
910 participants
Where
1 siteGermany
Study dates
1 Jan 2011to 30 Jun 2028
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Adult patients (≥18 years) with histologically confirmed colorectal cancer undergoing surgical treatment at a tertiary care center. The study includes both retrospectively collected patients (2011-2021) and prospectively enrolled patients (2026-2028) with available imaging and histopathological data.

Who may be able to join

  • Adult patients (≥18 years)
  • Histologically confirmed colorectal adenocarcinoma
  • Undergoing surgical resection (curative or palliative intent)
  • Availability of H\&E-stained whole-slide images (WSIs) from the primary tumour

Who cannot join

  • Patients not undergoing surgical treatment
  • Missing H\&E-stained tissue slides of the primary tumour
  • Histopathological material of insufficient quality for analysis

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Germany1 site, 1 recruiting
  • University Hospital Brandenburg an der Havel, Brandenburg an der Havel, Germany (Single-center)

    Brandenburg an der Havel

    Recruiting

Other trials in Germany

About this study

Official title: Staged Unimodal-to-Multimodal AI Analysis of Histopathology, CT/MRI, and Multiplex Tissue Imaging for Perioperative Risk Prediction in Colorectal Cancer (KIA-Korekt)

Perioperative complications following surgery for colorectal cancer (CRC) represent a major cause of postoperative morbidity and mortality. Existing risk stratification tools lack the precision to capture the complex biological and morphological factors that determine individual patient vulnerability. Artificial intelligence (AI)-based analysis of medical imaging data offers a promising approach to improve preoperative risk prediction.

The KIA-Korekt study investigates whether perioperative complications in CRC patients can be predicted using multimodal AI-based image analysis. Three complementary imaging modalities are integrated: digital histopathology (haematoxylin-eosin whole-slide images, H\&E-WSIs), preoperative CT and MRI radiomics, and multiplex tissue imaging (mTI) including multiplex immunohistochemistry (mIHC) and imaging mass cytometry (IMC).

Read more

The study includes a retrospective cohort of approximately 750 CRC patients treated between 2011 and 2021, and a prospective validation cohort of approximately 210 patients recruited from 2026 to 2028. Deep learning and radiomic feature extraction pipelines are applied to all modalities individually and in multimodal combination. Predicted outcomes include anastomotic leakage, wound infection, sepsis, ICU admission, and in-hospital mortality within 30 days of surgery.

The study is conducted at the University Hospital Brandenburg, Brandenburg Medical School Theodor Fontane, in collaboration with the Department of Computational Pathology, TU Dresden.

Read the detailed description

Colorectal cancer (CRC) is one of the most prevalent malignancies worldwide. Despite advances in surgical technique and perioperative care, short-term postoperative complications remain frequent and substantially impact patient quality of life, healthcare costs, and long-term prognosis. These complications include anastomotic leakage, wound infection, sepsis, thromboembolic events, and in-hospital mortality. Existing clinical risk scores (ASA, POSSUM) provide only limited individualised risk stratification and do not incorporate imaging-derived biological markers.

The KIA-Korekt study addresses this gap by developing and validating AI-based predictive models for perioperative complications in CRC, integrating three complementary imaging modalities:

Digital histopathology: Haematoxylin-eosin stained whole-slide images (H\&E-WSIs) from surgical resection specimens and preoperative biopsies are analysed using attention-based multiple instance learning (MIL) and convolutional neural networks (CNNs), building on established pipelines from the Department of Computational Pathology, TU Dresden (AG Kather).

Radiology: Preoperative CT and MRI images are processed using automated segmentation (TotalSegmentator, nnU-Net) and radiomic feature extraction (PyRadiomics). Features are derived from the primary tumour, psoas muscle (sarcopenia), and visceral/subcutaneous fat compartments. A dedicated multi-metric quality control pipeline ensures stable imaging data representations across scanners and acquisition protocols.

Multiplex tissue imaging (mTI): Multiplex immunohistochemistry with multispectral imaging (mIHC-MSI) and imaging mass cytometry (IMC) are applied to formalin-fixed paraffin-embedded tumour tissue to characterise immune and stromal cell populations, marker expression intensities, and spatial distribution patterns within the tumour microenvironment.

Unimodal models are developed and validated separately for each modality. Multimodal integration is performed using feature-level fusion, late fusion, and multimodal multiple-instance learning with cross-attention mechanisms. Model performance is evaluated using AUC-ROC, calibration plots, Brier scores, and Decision Curve Analysis. Interpretability is assessed using SHAP values and attention heatmaps.

The study employs a mixed retrospective (n=750, 2011-2021) and prospective validation (n=210, 2026-2028) cohort design. The retrospective cohort provides the basis for model development and internal cross-validation; the prospective cohort enables real-world external validation under clinical conditions.

A comprehensive patient-level macro-micro correlation analysis investigates associations between radiological imaging phenotypes and microscopic histopathological and immunological characteristics derived from the same tumours, enabling unique integrative biological insights.

The study is funded by the European Union and the State of Brandenburg (HealthTranslateBB/ERDF) and the German Research Foundation (DFG). Ethics approval has been granted by the ethics committee of the Brandenburg Medical School Theodor Fontane. All prospective participants provide written informed consent. Retrospective data are processed in pseudonymised form in accordance with GDPR.

Results will be disseminated through peer-reviewed open-access publications and national and international conference presentations.

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07537491
Study groupRoleWhat they receive
Group 1: Retrospective Training CohortPatients with colorectal cancer treated between 2011-2021 with available imaging and histopathology data.
Prospective CohortPatients with colorectal cancer enrolled prospectively between 2026-2028.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Prediction accuracy of perioperative complications

    Occurrence of postoperative complications including anastomotic leakage, sepsis, ICU admission, and in-hospital mortality. Outcomes are defined based on clinical documentation and assessed as binary variables (yes/no).

    Measured: 30 days postoperative

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Apr 2026
  2. Study start1 Jan 2011
  3. Primary completion31 Dec 2027 (estimated)
  4. Study completion30 Jun 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
910 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07537491
Sponsor's protocol ID
KIA-Korekt-2025
Acronym
KIA-Korekt
Status last verified
Apr 2026
First submitted
8 Apr 2026
Last updated
17 Apr 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes

Questions about this trial

What is this clinical trial studying?

An observational study of Colorectal Cancer Postoperative Complications, run by Rene Mantke at 1 site in Germany.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 17 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Melissa Horner, MSc (+4915207809673, melissa.schadl@mhb-fontane.de), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Prediction accuracy of perioperative complications (time frame: 30 days postoperative). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Apr 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in